Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

Medicinal Research Reviews

Volumn 16, Issue 3, 1996, Pages 243-266

  Smith, Dennis A ^a   Jones, Barry C ^a   Walker, Donald K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 9 AMINO 8 FLUORO 1,2,3,4 TETRAHYDRO 2,4 METHANOACRIDINE; AMLODIPINE; ATENOLOL; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM ANTAGONIST; CHLORPROPAMIDE; CHOLINESTERASE INHIBITOR; CYTOCHROME P450; DICLOFENAC; DIHYDROPYRIMIDINE DERIVATIVE; DILTIAZEM; DOFETILIDE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FENCLOFENAC; FLUCONAZOLE; KETOCONAZOLE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROPRANOLOL; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BILIARY EXCRETION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; INTESTINE ABSORPTION; KIDNEY CLEARANCE; LIPOPHILICITY; MEMBRANE TRANSPORT; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; REVIEW; SPECIES DIFFERENCE; THEORY;

ABSORPTION; AMLODIPINE; ANTI-ARRHYTHMIA AGENTS; ANTIFUNGAL AGENTS; ANTIHYPERTENSIVE AGENTS; CHEMISTRY, PHYSICAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; FLUCONAZOLE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; PHENETHYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0029865450     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-1128(199605)16:3<243::aid-med2>3.3.co;2-r     Document Type: Article

References (54)

1. R. A. Prentis, Y. Lis, and S. R. Walker, Br. J. Clin. Pharmacol., 25, 387 (1988).
2. M. J. Humphrey and D. A. Smith, Xenobiotica, 22, 743 (1992).
3. S-H. L. Chiu, J. Pharmacol. Meth., 29, 77 (1993).
4. R. N. Smith, C. Hansch, and M. M. Ames, J. Pharm. Sci., 64, 599 (1975).
5. C. N. Manners, D. W. Payling, and D. A. Smith, Xenobiotica, 18, 331 (1988).
6. A. Leo, J. Pharm. Sci., 76, 166 (1987).
7. D. A. Stopher and S. M. McClean, J. Pharm. Pharmacol., 42, 144 (1990).
8. M. H. Abraham, W. R. Lieb, and N. P. Franks, J. Pharm. Sci., 80, 719 (1991).
9. D. A. Smith, M. J. Humphrey, and C. Charuel, Xenobiotica, 20, 1187 (1990).
10. M. S. Karls, B. D. Rush, K. F. Wilkinson, T. J. Vidmar, P. S. Burton, and M. J. Ruwart, Pharm. Res., 8, 1477 (1991).
11. S. H. Rosenberg, K. P. Spina, K. W. Woods, J. Polakowski, D. L. Martin, Z Yao, H. H. Stein, J. Cohen, J. L. Barlow, D. A. Egan, K. A. Tricarico, W. R. Baker, and H. D. Kleinert, J. Med. Chem., 36, 449 (1993).
12. D-C. Kim, P. S. Burton, and R. T. Borchardt, Pharm. Res., 10, 1710 (1993).
13. K. C. Beaumont, P. V. Macrae, C. M. Miller, D. A. Smith, and P. Wright, Br. J. Clin. Pharmacol., 38, 179P (1994).
14. R. A. Herman and P. Veng-Pedersen, J. Pharm. Sci., 83, 423 (1994).
15. D. A. Stopher, A. P. Beresford, P. V. Macrae, and M. J. Humphrey, J. Cardiovasc. Pharmacol., 12, S55 (1988).
16. B. Edgar, C. G. Regardh, G. Johnsson, L. Johansson, P. Lundborg, I. Lofberg, and O. Ronn, Clin. Pharmacol. Ther., 38, 205 (1985).
17. R. P. Mason, D. G. Rhodes, and L. G. Herbette, J. Med. Chem., 34, 869 (1991).
18. D. Alker, R. A. Burges, S. F. Campbell, A. J. Carter, P. E. Cross, D. G. Gardiner, M. J. Humphrey, and D. A. Stopher, J. Chem. Soc. Perkin Trans. 2, 1137 (1992).
19. G. Foulds, R. M. Shepard, and R. B. Johnson, J. Antimicrob. Chemother., 25, 73 (1990).
20. N. J. Lalak and D. L. Morris, Clin. Pharmacokinet., 25, 370 (1993).
21. C. S. Cook, S. J. McDonald, and A. Karim, Xenobiotica, 23, 1299 (1993).
22. S. Vozeh, O. Schmidlin, and W. Taeschner, Clinical Pharmacokinetics Drug Data Handbook, Adis Press Ltd., Auckland, 1989, p. 1.
23. D. A. Smith, H. S. Rasmussen, D. A. Stopher, and D. K. Walker, Xenobiotica, 22, 709 (1992).
24. R. C. Young, R. C. Mitchell, T. H. Brown, C. R. Ganellin, R. Griffiths, M. Jones, K. K. Rana, D. Saunders, I. R. Smith, N. E. Sore, and T. J. Wilks, J. Med. Chem., 31, 656 (1988).
25. M. Yabuki, T. Mine, K. Iba, I. Nakatsuka, and A. Yoshitake, Drug Metab. Dispos., 22, 294 (1994).
26. D. A. Smith, K. Brown, and M. G. Neale, Drug Metab. Rev., 16, 365 (1985).
27. B. C. Jones, R. Hyland, D. A. Smith, and D. K. Walker, Br. J. Clin. Pharmacol., 38, 170P (1994).
28. P. Stjernlof, M. Gullme, T. Elebring, B. Andersson, H. Wikstrom, S. Lagerquist, K. Svensson, A. Ekman, A. Carlsson, and S. Sundell, J. Med. Chem., 36, 2059 (1993).
29. D. A. Smith and B. C. Jones, Biochem. Pharmacol., 44, 2089 (1992).
30. F. P. Guengerich and T. L. Macdonald, FASEB J, 4, 2453 (1990).
31. K. R. Korzekwa and J. P. Jones, Pharmacogenetics, 3, 1 (1993).
32. G. R. Strobl, S. von Kruedener, J. Stöckigt, F. P. Guengerich, and T. Wolff, J. Med. Chem., 36, 1136 (1993).
33. B. C. Jones, G. Hawksworth, V. Horne, A. Newlands, M. S. Tute, and D. A. Smith, Br. J. Clin. Pharmacol., 36, 143P (1993).
34. P. M. Manoury, J. L. Binet, J. Rousseau, F. M. Leferre-Borg, and I. G. Cavero, J. Med. Chem., 30, 1003 (1987).
35. P. Marchetti and R. Navalesci, Clin. Pharmacokinet., 16, 100 (1989).
36. A. J. Newlands, D. A. Smith, B. C. Jones, and G. M. Hawksworth, Br. J. Clin. Pharmacol., 34, 152P (1992).
37. R. K. Verbeck, J. L. Blackburn, and G. R. Loewen, Clin. Pharmacokinet., 8, 297 (1983).
38. L. Pichard, G. Gillet, I. Fabre, I. Dalet-Beluche, C. Bonfils, J-P. Thenot, and P. Maurel, Drug Metab. Dispos., 18, 711 (1990).
39. D. M. Floyd, S. D. Dimball, J. Krapcho, J. Das, C. F. Turk, R. V. Moquin, M. W. Lago, K. J. Duff, V. G. Lee, R. E. White, R. E. Ridgewell, S. Moreland, R. J. Brittain, D. E. Normandin, S. A. Hedberg, and G. C. Cucinotta, J. Med. Chem., 35, 756. (1992).
40. F. P. Guengerich, W. R. Brian, M. Iwasaki, M-A. Sari, C. Baarnhielm, and P. Bertsson, J. Med. Chem., 34, 1838 (1991).
41. D. A. Smith, Drug Metab. Rev., 23, 355 (1991).
42. M. J. Humphrey, Xenobiotic Metabolism and Disposition, Taylor and Francis, London, 1989, pp. 245-253.
43. K. S. Atwal, B. N. Swanson, S. E. Unger, D. M. Floyd, S. Moreland, A. Hedberg, and B. C. O'Reilly, J. Med. Chem., 34, 806 (1991).
44. I. B. Gardner, D. K. Walker, M. S. Lennard, D. A. Smith, and G. T. Tucker, Xenobiotica, 25, 185 (1995).
45. D. K. F. Meijer and G. M. M. Groothuis, Oxford Textbook of Clinical Hepatology, Vol. 1, Oxford University Press, Oxford, 1991, p. 40.
46. J. Singh, P. Conzentino, K. Cundy, J. A. Gainor, C. L. Gilliam, T. D. Gordon, J. A. Johnson, B. A. Morgan, E. D. Schneider, R. C. Wahl, and D. A. Whipple, Bioorg. Med. Chem. Lett., 5, 337, (1995).
47. G. A. LeBlanc, Chem.-Biol. Interact., 90, 101 (1994).
48. I. A. M. DeLannoy and M. Silverman, Biochem. Biophys. Res. Commun., 189, 551 (1992).
49. D. A. Smith, K. Beaumont, N. J. Cussans, M. J. Humphrey, S. G. Jezequel, D. J. Rance, D. A. Stopher, and D. K. Walker, Xenobiotica, 22, 1195 (1992).
50. D. K. Walker, C. T. Alabaster, G. S. Congrave, B. C. Jones, and D. A. Smith, Br. J. Clin. Pharmacol., 37, 499P (1994).
51. S. G. Jezequel, J. Pharm. Pharmacol., 46, 196 (1994).
52. L. Brown, N. M. Deighton, S. Bals, W. Söhlmann, H-R. Zerkowski, M. C. Michel, and O-E. Brodde, J. Cardiovasc. Pharmacol., 19, 222 (1992).
53. Y. Yamada, K. Ito, K. Nakamura, Y. Sawada, and T. Iga, Biol. Pharm. Bull., 16, 1251 (1993).
54. M. L. West and D. P. Farlie, TIPS, 16, 33 (1995).